- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that there has been no material development in its business affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action regarding its share price. The post Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger appeared first on Impact Biomedical, Inc..
Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that there has been no material development in its business affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action regarding its share price. The post Impact Biomedical Inc. Announcement Stock Activity / Pricing appeared first on Impact Biomedical, Inc..
Impact Biomedical Inc. Announces Acquisition of Celios®, “Protecting People, Plants, and Animals from the World’s Most Dangerous Pathogens With Clean-Room Air Quality” The post Impact Biomedical Inc. Announces Acquisition of Celios® appeared first on Impact Biomedical, Inc..
Impact Biomedical Inc. today announced that Frank D. Heuszel, Chief Executive Officer, is pleased to announce his participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The post Impact BioMedical Inc. to Present at The Microcap Conference appeared first on Impact Biomedical, Inc..
We closed our first quarter as a publicly traded company and wanted to address all current and future stakeholders highlighting our recent achievements, our appreciation for your support, and some additional insights into why we are excited for the future and continued success of Impact BioMedical Inc! The post Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision appeared first on Impact Biomedical, Inc..
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBIO), in which DSS Inc. (NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Laetose™ technology platform. The U.S. Patent and Trademark Office (USPTO) has issued U.S. patent # 11,898,184, entitled "Low Glycemic Sugar Composition" developed within this platform. The post Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled “Low Glycemic Sugar Composition.” appeared first on Impact Biomedical, Inc..
